NCT06840769 - A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2023

Primary Completion Date

October 18, 2023

Study Completion Date

October 23, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

Fosnetupitant 235 mg solution

Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration

DRUG

Akynzeo solution

235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution

Trial Locations (1)

CH-6864

CROSS Research S.A., Arzo